The Long Quest for Artificial Blood

Scientists are making significant advances in developing artificial blood substitutes, with two promising approaches emerging in 2025, the New Yorker reports. At the University of Maryland School of Medicine’s Center for Blood Oxygen Transport and Hemostasis, researchers are testing ErythroMer, a synthetic nanoparticle that mimics red blood cells’ oxygen-carrying capabilities. Simultaneously, the UK’s National Health Service is conducting the first human trials of lab-grown blood cells.

These developments address critical blood shortages – of the 38% of Americans eligible to donate, less than 3% do so regularly. Traditional donated blood also has significant limitations: platelets last only 5 days, red blood cells 42 days, and all require careful refrigeration and blood-type matching. DARPA awarded $46 million in early 2023 to develop ErythroMer, seeing potential for battlefield medicine where traditional blood storage isn’t feasible.

The synthetic blood can be stored as a powder and reconstituted when needed. There are still a lot of challenges, the report adds. The lab-grown blood currently costs about $75,000 per syringe compared to around $200 for a pint of donated blood, and production is limited to small quantities.